Eolo Pharma Company Research Report

Company Overview

Name and Mission

• Company Name: Eolo Pharma

• Mission: To create well-being through innovative and personalized therapeutic solutions, with a commitment to improving the quality of life for patients.

Founding Details

• Founded By: Carlos Batthyany, Virginia Lopez, Carlos Escande, and María Pía Garat.

• Origin: Eolo Pharma was founded as a scientific spin-off from the Institut Pasteur de Montevideo and Universidad de la República, Uruguay.

Key People

• CEO: María Pía Garat

• CSO: Carlos Escande

• CCO: Virginia Lopez

• CMO: Carlos Batthyany

Headquarters

• Location: Delaware, USA

Number of Employees

• Information Unavailable

Revenue

• Information Unavailable

Core Competency

• Known For: Developing novel therapeutic solutions focusing on non-communicable disorders such as cardiometabolic, neurodegenerative, and autoimmune disorders.

Products

Product Portfolio

MVD-1

• Description: MVD1 is a lead compound designed to target obesity and its associated comorbidities, such as type II diabetes and cardiovascular disorders.

• Key Features:

• Anti-obesity properties demonstrated in preclinical models.

• Improves glucose metabolism.

• Stimulates energy expenditure and fat burning.

• Potential treatment for type II diabetes with better results than Metformin.

• Has undergone preclinical development and complies with regulatory safety requirements.

Additional Compounds

• NCE Library: Composed of 60 novel molecules.

• MVD1 Analog: Under development for similar indications.

• ALS/Alzheimer's Pipeline: Includes innovative NF-kB inhibitors like the Eolo40 compound for neurodegenerative conditions.

Recent Developments

Clinical Trials and Regulatory Approvals

• May 6, 2024: Eolo Pharma announced regulatory clearance to initiate a Phase 1 study for MVD1 targeting obesity and type II diabetes.

• May 22, 2024: Eolo Pharma began dosing subjects in Phase 1 clinical trials of MVD1 to tackle both obesity and its cardiometabolic complications.

Scientific Contributions

• Engagement in groundbreaking research with numerous peer-reviewed publications focusing on obesity, ALS, and other significant healthcare challenges.

• Developed nitroalkene benzoic acid derivative to target reactive microglia and prolong survival in ALS models, demonstrating NF-κB inhibition.

Partnerships and Collaborations

• Eolo Pharma collaborates with Instituto Pasteur de Montevideo and Universidad de la República, Uruguay, often integrating academic research with industry applications.

• Information on New Partnerships: No new partnerships announced within the provided timeline.

Conclusion

Eolo Pharma stands at the forefront of pharmaceutical innovation, striving to combine cutting-edge medical science with therapeutic solutions to improve patient quality of life. With a strong focus on non-communicable diseases, particularly the global epidemic of obesity, and its collaborations with prestigious research institutions, Eolo Pharma is strategically positioned to influence and advance global healthcare.